Is Riboflavin Fatigue Randomized Trial safe?

Updated August 2026

Quick Answer

Riboflavin Fatigue Randomized Trial has evidence relevant to safety, limits, and clinician-discussion contexts, but conclusions should stay close to the cited sources. One representative finding is: The etiology of fatigue in IBD is multifactorial and may be associated with inflammation, anemia, nutrient deficiencies, medications, and microbiota.

Key Takeaways

  • 01The etiology of fatigue in IBD is multifactorial and may be associated with inflammation, anemia, nutrient deficiencies, medications, and microbiota. [MORAIS Tayane (2026)]
  • 02Fatigue in patients with IBD is associated with decreased physical functioning, mood disturbances, and low productivity, presenting symptoms of physical and mental exhaustion. [MORAIS Tayane (2026)]
  • 03The guiding question for this study was: what is the current scientific evidence, over the last seven years, on the pharmacological treatment of fatigue in patients with IBD? [MORAIS Tayane (2026)]
  • 04, , Inflammatory bowel disease (IBD) is a chronic inflammatory condition that results from the interaction between genetic and environmental factors that influence immune responses and one’s quality of life. [MORAIS Tayane (2026)]
The current Migaku evidence database contains 1 reusable source document for Riboflavin Fatigue Randomized Trial. This answer focuses on safety, limits, and clinician-discussion contexts. - The etiology of fatigue in IBD is multifactorial and may be associated with inflammation, anemia, nutrient deficiencies, medications, and microbiota. [MORAIS Tayane (2026); evidence level 4] - Fatigue in patients with IBD is associated with decreased physical functioning, mood disturbances, and low productivity, presenting symptoms of physical and mental exhaustion. [MORAIS Tayane (2026); evidence level 4] - The guiding question for this study was: what is the current scientific evidence, over the last seven years, on the pharmacological treatment of fatigue in patients with IBD? [MORAIS Tayane (2026); evidence level 4] - , , Inflammatory bowel disease (IBD) is a chronic inflammatory condition that results from the interaction between genetic and environmental factors that influence immune responses and one’s quality of life. [MORAIS Tayane (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.

Sources

  1. PHARMACOLOGICAL TREATMENTS FOR FATIGUE IN INFLAMMATORY BOWEL DISEASE PATIENTS: AN INTEGRATIVE REVIEW